Stocks · News reference
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.
Read original at benzingaNewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 246.67 percent decrease over losses of $(0.15) per share
Read original at benzinga